HRT Financial’s Biotech Acquisition Company Unit BIOTU Stock Holding History

HRT Financial’s Portfolio BIOTU Stock Details BIOTU Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-89,754	Closed	-$889K	–	4019
2022 Q1	$889K	Hold	89,754	–	–	0.01%	1160
2021 Q4	$900K	Hold	89,754	–	–	0.01%	1229
2021 Q3	$902K	Hold	89,754	–	–	0.01%	1435
2021 Q2	$906K	Hold	89,754	–	–	0.01%	1203
2021 Q1	$887K	Buy	+89,754	New	+$923K	0.01%	1268

Other funds holding BIOTU

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

HRT Financial's BIOTU Position: Q2 2022 in Review

HRT Financial sold out of Biotech Acquisition Company Unit (BIOTU) in Q2 2022, closing a stake of 89,754 shares — an estimated $889K sold.

HRT Financial first reported a position in BIOTU in Q1 2021 and held it in 5 quarters. The position peaked at $906K in Q2 2021. 5 funds tracked by Wall St. Rank hold BIOTU as of Q2 2022.

HRT Financial reported no remaining Biotech Acquisition Company Unit position as of Q2 2022 after selling out during the quarter.
HRT Financial sold 89,754 Biotech Acquisition Company Unit shares in Q2 2022, an estimated $889K.
HRT Financial first reported a position in Biotech Acquisition Company Unit in Q1 2021 and held it in 5 quarters.
HRT Financial's Biotech Acquisition Company Unit position peaked at $906K in Q2 2021.
5 funds tracked by Wall St. Rank held Biotech Acquisition Company Unit as of Q2 2022.

Based on HRT Financial's 13F filing for Q2 2022, filed 12 Aug 2022.